arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

BIOVIE INC.

BIVI
$1.02 ▼ -0.33 (-24.72%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
13 Visible periods
21 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

BIOVIE INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.5M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -75.1%
FCF / Share $-12.88
Trailing P/E
Price / Book 0.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

13-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-17.54M
↑ +45.4%
FCF / Share Free cash flow per share
$-12.88
↓ -108.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
10
Financial Health
16
Cash Quality
69

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 53 quarters